山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00719 山东新华制药股份

未开盘 10-27 16:08:19

5.360

-0.040

-0.74%

最高5.440	最低5.335	成交量15.40万
今开5.365	昨收5.400	日振幅1.94%
总市值37.36亿	流通市值10.45亿	总股本6.97亿
成交额82.98万	换手率0.08%	流通股本1.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":5.36,"timestamp":1793088499415,"preClose":5.4,"halted":0,"volume":154000,"delay":0,"changeRate":-0.007407407407407414,"floatShares":195000000,"shares":697000000,"eps":0.49433179325870896,"marketStatus":"未开盘","change":-0.04,"latestTime":"10-27 16:08:19","open":5.365,"high":5.44,"low":5.335,"amount":829830,"amplitude":0.019444,"askPrice":5.44,"askSize":4000,"bidPrice":5.36,"bidSize":46000,"shortable":0,"etf":0,"ttmEps":0.3653900529090153,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793151000000},"marketStatusCode":0,"adr":0,"listingDate":851961600000,"exchange":"SEHK","adjPreClose":5.4,"dividendRate":0.032928,"openAndCloseTimeList":[[1793064600000,1793073600000],[1793077200000,1793088000000]],"volumeRatio":0.5100013246956552,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":12.31,"timestamp":1793084400000,"preClose":12.79,"halted":0,"volume":11500300,"delay":0,"premium":"-63.01"}},"requestUrl":"/m/hq/s/00719","defaultTab":"news","newsList":[{"id":"1180015998","title":"山东新华制药（00719）尼莫地平片获一致性评价 强化市场竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=1180015998","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180015998?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:12","pubTimestamp":1792404756,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司10月19日披露，其尼莫地平片已获国家药品监督管理局签发的《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价。公告显示，新华制药于2025年7月向国家药监局药品审评中心提交尼莫地平片一致性评价申报材料，并于2026年10月获批。根据公告援引的统计数据，2025年中国公立医疗机构尼莫地平片销售额约为1.3亿元。公司认为，通过一致性评价有助于提升该产品的市场竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192758043","title":"山东新华制药(00719)将于11月10日召开临时股东大会 审议委任刘伟民为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1192758043","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192758043?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:45","pubTimestamp":1792140341,"startTime":"0","endTime":"0","summary":"- 参会资格：截至11月3日在香港中央证券登记有限公司及中国证券登记结算深圳分公司名册上的股东，以及公司董事、高管","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135125932","title":"山东新华制药(00719)公告10月28日召开董事会 审议截至9月30日止九个月未审计业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1135125932","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135125932?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:36","pubTimestamp":1791966979,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司（00719）10月14日发布公告称，董事会已发出会议通知，定于2026年10月28日（星期三）上午9时30分在中国山东省淄博市高新区鲁泰大道1号公司会议室召开董事会会议。此次会议的主要议程包括：\n1. 审议并批准公司及其附属公司截至2026年9月30日止九个月的未审计业绩；\n2. 处理任何其他相关事宜（如适用）。\n公告同时披露，当前董事会成员包括：执行董事贺同庆（董事长）、徐文辉、侯宁；独立非执行董事潘广成、朱建伟、凌沛学、张菁菁；非执行董事张成勇。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675337173","title":"山东新华制药股份(00719)董事会秘书曹长求拟减持不超过8.33万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2675337173","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675337173?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:27","pubTimestamp":1791883670,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)公布，公司于近日收到公司董事会秘书曹长求先生发送的《股份减持计划告知函》，其计划在本公告发布之日起的 15 个交易日之后的 3 个月内以集中竞价方式减持公司股份不超过8.33万股，占公司总股本的 0.012%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","00719","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177906139","title":"山东新华制药股份（00719）披露高管拟减持不超8.33万股  占总股本0.012%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177906139","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177906139?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:22","pubTimestamp":1791883326,"startTime":"0","endTime":"0","summary":"曹长求目前持有公司A股333,200股，占公司总股本的0.048%。根据减持计划，其拟于本公告披露之日起15个交易日后的3个月内，以集中竞价方式减持不超过83,300股，占公司总股本的0.012%。公告指出，本次减持符合《上市公司股东减持股份管理暂行办法》等相关法规的规定，减持实施不会导致公司控制权发生变更，也不会对公司治理结构、股权结构及持续经营产生重大影响。公司承诺在减持期间严格履行信息披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174300690","title":"山东新华制药(00719)拟委任刘伟民为执行董事 月薪4.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174300690","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174300690?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:42","pubTimestamp":1791538952,"startTime":"0","endTime":"0","summary":"10月9日，山东新华制药股份有限公司发布公告称，董事会已决议提名刘伟民为执行董事候选人。该任命尚需提交预计于2026年11月10日前后召开的临时股东大会，并以普通决议案形式获得股东批准后方可生效。根据公告，刘伟民的任期拟自股东大会批准当日起至公司第十一届董事会届满之日止。经股东批准后，公司将与刘伟民签订服务合约，月度基础薪酬建议为人民币4.33万元。2026年9月起，刘伟民加入山东新华制药股份有限公司并担任党委书记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674130830","title":"山东新华制药股份(00719)：刘伟民获委任为执行董事的候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2674130830","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674130830?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:37","pubTimestamp":1791538675,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)发布公告，董事会已议决建议刘伟民先生(刘先生)为获委任为执行董事的候选人，惟须待本公司的股东在将于2026年11月10日或前后举行的本公司临时股东会上批准后方可作实，此乃基于董事会提名委员会提出的推荐。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131712876","title":"山东新华制药（00719）取得沙库巴曲缬沙坦钠片注册证书，切入年销78亿元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1131712876","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131712876?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:56","pubTimestamp":1791449769,"startTime":"0","endTime":"0","summary":"2026年10月8日，山东新华制药股份有限公司公告称，已于2026年10月收到国家药品监督管理局核准签发的沙库巴曲缬沙坦钠片《药品注册证书》，产品规格为沙库巴曲缬沙坦计50mg，注册分类为化学药品4类，剂型为片剂，药品属性为处方药。新华制药于2025年4月向国家药品监督管理局药品审评中心递交上市许可注册申报，并于2026年10月获批准注册。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166169986","title":"山东新华制药股份9月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1166169986","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166169986?lang=zh_cn&edition=full","pubTime":"2026-10-07 14:35","pubTimestamp":1791354935,"startTime":"0","endTime":"0","summary":"山东新华制药股份于2026年10月7日发布2026年9月股份变动月报表。报告期为2026年9月1日至9月30日，公司法定注册股本及已发行股份情况维持不变。公司法定注册股本方面，普通股H股于上月底结存195,000,000股、A股于上月底结存501,683,435股，报告期内未发生增减变动。本月底公司法定注册股本总额仍保持在人民币696,683,435元。截至本月底，未有新增行权或由库存转让的股份数目，上述期权在报告期内无变动。本次公告由公司秘书曹长求签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129190178","title":"山东新华制药（00719）副总经理刘雪松辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1129190178","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129190178?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:56","pubTimestamp":1790672187,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司9月29日公告称，公司董事会于2026年9月29日收到副总经理刘雪松的书面辞职报告。刘雪松因工作变动原因，辞去公司副总经理及在公司担任的其他一切职务，辞职自送达董事会之日起生效。\\n\\n公告显示，刘雪松在任职期间与董事会无意见分歧，亦不存在需提请股东注意的其他事项。\\n\\n截至公告披露日，刘雪松持有公司A股223,100股。\\n\\n董事会对刘雪松先生在任期间所作出的贡献表示感谢。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671629736","title":"山东新华制药股份(00719.HK)：刘雪松辞任副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2671629736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671629736?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:53","pubTimestamp":1790672016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00719","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110097","title":"山东新华制药股份(00719)：A股股票交易异常波动 前期披露的信息不存在需要更正、补充之处","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669110097?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:31","pubTimestamp":1790069478,"startTime":"0","endTime":"0","summary":"针对公司股票异常波动，公司对有关事项进行了核查，有关情况说明如下： 1、经核查，公司前期披露的信息不存在需要更正、补充之处。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02846","BK1515","83188","03188","BK1191","07233","00719","399300","BK1147","02827","82846","03130","83130","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145497097","title":"山东新华制药：A股三日累涨偏离20% 公司称无未披露重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1145497097","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145497097?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:30","pubTimestamp":1790069433,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司9月22日公告称，其A股股票于2026年9月18日、9月21日及9月22日连续三个交易日收盘价格涨幅偏离值累计达到20%，根据深圳证券交易所相关规定，构成股票交易异常波动。公司表示，经内部核查及向控股股东、实际控制人问询，近期经营情况及内外部经营环境未发生重大变化，亦不存在应披露而未披露的重大事项，控股股东和实际控制人在上述期间未买卖公司股票。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192086388","title":"山东新华制药股份2026年上半年营收43.58亿元，经调整净利润1.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192086388","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192086388?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:48","pubTimestamp":1790066919,"startTime":"0","endTime":"0","summary":"2026年上半年，山东新华制药股份公告显示，公司实现营业收入约43.58亿元，同比下降6.06%；经调整后净利润约1.47亿元，同比下降30.14%。本期销售费用约1.68亿元，同比下降2.82%；管理费用约2.07亿元，同比下降3.80%；研发投入约1.92亿元，同比下降5.16%；财务费用则增长显著，同比增长208.72%。报告期内，经营活动产生的现金流量净额约为1.61亿元，同比下降31.40%。公司继续在研发端保持投入，报告期内研发占比维持在较高水平，为后续新产品及创新药布局提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份2026年上半年营收43.58亿元，经调整净利润1.47亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669580151","title":"A股收评：超4500股上涨！沪指涨0.97%，创新药、地产板块爆发，“华字辈”现涨停潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2669580151","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669580151?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:05","pubTimestamp":1789974303,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1993786604.SGD","LU1807302812.USD","BK0113","BK0273","BK0164","LU1655091616.SGD","BK0278","BK0239","LU0501845795.SGD","BK0188","LU1580142542.USD","000001","BK0012","BK0190","600664","BK0028","BK0216","BK0201","IE00B0JY6N72.USD","BK0183","BK0102","LU1781817850.SGD","000756","LU0072913022.USD","BK0095","002285","LU0067412154.USD","00719","BK0187","LU0880133367.SGD","600721","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","03600","02196","06699","06826","01530","BK1100","BK1191","BK1515","HK0000165453.HKD","BK1583","BK1161","00719","BK1587","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669710136","title":"港股异动 | 山东新华制药股份(00719.HK)早盘涨超8% 左卡尼汀口服溶液等获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2669710136","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669710136?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:54","pubTimestamp":1789955673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00719","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187346461","title":"山东新华制药（00719）子公司获盐酸多奈哌齐口崩片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1187346461","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187346461?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:07","pubTimestamp":1789722468,"startTime":"0","endTime":"0","summary":"2026年9月18日，山东新华制药股份公告称，其全资子公司山东淄博新达制药有限公司已收到国家药品监督管理局核准签发的盐酸多奈哌齐口崩片《药品注册证书》。新达制药于2025年2月提交上市许可申请，2026年9月获批注册。盐酸多奈哌齐口崩片适用于轻度、中度或重度阿尔茨海默病症状的治疗，已被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》乙类品种。公司表示，本次获批有利于丰富其中枢神经领域产品系列，提升综合竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198107025","title":"山东新华制药（00719）获得硫酸镁钠钾口服用浓溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1198107025","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198107025?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:06","pubTimestamp":1789722363,"startTime":"0","endTime":"0","summary":"9月18日，山东新华制药股份有限公司公告称，公司已收到国家药品监督管理局签发的硫酸镁钠钾口服用浓溶液《药品注册证书》。该品种注册分类为化学药品4类，剂型为口服溶液剂，规格为176ml：硫酸镁3.276g、硫酸钠17.510g、硫酸钾3.130g，为处方药。硫酸镁钠钾口服用浓溶液已被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》乙类范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137989613","title":"山东新华制药（00719）获批左卡尼汀口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1137989613","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137989613?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:06","pubTimestamp":1789722363,"startTime":"0","endTime":"0","summary":"2026年9月18日，山东新华制药股份有限公司公告称，其收到国家药品监督管理局核准签发的左卡尼汀口服溶液《药品注册证书》，标志着该产品正式获准在境内生产并上市销售。本次获批的左卡尼汀口服溶液剂型为口服溶液剂，规格为10ml：1g，药品类别为处方药，注册分类为化学药品4类。公司表示，左卡尼汀口服溶液的获批将进一步丰富其口服代谢调节制剂产品线，提升市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.0711},{"period":"3month","weight":-0.1532},{"period":"6month","weight":-0.1082},{"period":"1year","weight":-0.2158},{"period":"ytd","weight":-0.1622}],"compareEarnings":[{"period":"1week","weight":-0.0346},{"period":"1month","weight":-0.0599},{"period":"3month","weight":-0.1072},{"period":"6month","weight":-0.1061},{"period":"1year","weight":-0.1283},{"period":"ytd","weight":-0.101}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东新华制药股份有限公司是一家主要从事化学原料药、制剂及化工产品的开发、制造和销售的中国公司。该公司运营三个分部。化学原料药分部主要从事咖啡因系列、布洛芬系列、阿司匹林系列、多巴系列、巴比妥系列及吡哌酸等解热镇痛类原料药的开发、制造及销售。制剂分部主要从事吡哌酸片、安痛定及尼莫地平片等片剂、针剂及胶囊剂等制剂的开发、制造及销售。医药中间体及其他产品分部主要从事医药中间体及其他产品的开发、制造及销售。该公司主要在中国国内市场及美洲和欧洲等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.012135},{"month":2,"riseRate":0.766667,"avgChangeRate":0.099902},{"month":3,"riseRate":0.433333,"avgChangeRate":-0.007748},{"month":4,"riseRate":0.7,"avgChangeRate":0.100629},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.000855},{"month":6,"riseRate":0.433333,"avgChangeRate":-0.005711},{"month":7,"riseRate":0.6,"avgChangeRate":0.01986},{"month":8,"riseRate":0.275862,"avgChangeRate":-0.043444},{"month":9,"riseRate":0.37931,"avgChangeRate":-0.016386},{"month":10,"riseRate":0.433333,"avgChangeRate":0.006109},{"month":11,"riseRate":0.551724,"avgChangeRate":0.012197},{"month":12,"riseRate":0.586207,"avgChangeRate":0.023647}],"exchange":"SEHK","name":"山东新华制药股份","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山东新华制药股份,00719,山东新华制药股份股票,山东新华制药股份股票老虎,山东新华制药股份股票老虎国际,山东新华制药股份行情,山东新华制药股份股票行情,山东新华制药股份股价,山东新华制药股份股市,山东新华制药股份股票价格,山东新华制药股份股票交易,山东新华制药股份股票购买,山东新华制药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}